Zacks upgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a neutral rating to an outperform rating in a research note released on Monday morning, AmericanBankingNews.com reports. They currently have $5.40 target price on the stock. Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) opened at 4.81 on Monday. Sunesis Pharmaceuticals has a 52 week low of $4.26 and a […]
Sunesis Pharmaceuticals Stock Rating Upgraded by Zacks (SNSS) is a post from: Zolmax
The post Sunesis Pharmaceuticals Stock Rating Upgraded by Zacks (SNSS) appeared first on Zolmax.